Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com
by Jessica Moore · The Cerbat GemStockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report report published on Thursday. The brokerage issued a sell rating on the stock.
Oragenics Stock Performance
OGEN opened at $1.04 on Thursday. The stock’s 50 day moving average price is $1.61. Oragenics has a 52 week low of $0.97 and a 52 week high of $7.74. The firm has a market capitalization of $4.66 million, a price-to-earnings ratio of -0.12 and a beta of 0.58.
Oragenics (NYSE:OGEN – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share for the quarter.
Institutional Trading of Oragenics
An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new position in Oragenics, Inc. (NYSE:OGEN – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the Securities & Exchange Commission. 18.71% of the stock is owned by hedge funds and other institutional investors.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Stories
- Five stocks we like better than Oragenics
- What is the Shanghai Stock Exchange Composite Index?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- MarketBeat Week in Review – 6/24 – 6/28
- What Investors Need to Know About Upcoming IPOs
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024